Skin sterol identifies multivessel disease risk
This article was originally published in Clinica
Measurements from IMI International Medical Innovations' noninvasive, point-of-care skin sterol test, PREVU, when combined with a patient's cardiac disease risk as classified by the Framingham global risk score, could pinpoint patients with a higher risk of multivessel disease - ie narrowing in two or more coronary vessels. So revealed a 649-patient study that found that when skin sterol and Framingham risk were both elevated, the likelihood of multivessel disease was four times greater. Toronto, Canada-based IMI has already received clearance to sell PREVU in the US, Canada and Europe for assessing coronary artery disease risk. In a separate announcement, the firm said it was launching a 78-patient pivotal clinical study of its non-invasive breast cancer detection test, which identifies a cancer-associated sugar in nipple-aspirate fluid.